Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504642 | 0.83 | MEN1 (0.83) | RXFP1KMT2AMEN1RAB9AKCNK3 | |
| SCHEMBL6778380 | 0.83 | SGMS2 (0.76) | RXFP1KCNK3KCNK9SGMS2HSD17B10 | |
| SCHEMBL7632984 | 0.81 | ALDH1A1 (0.71) | KMT2AMEN1RAB9ASGMS2HSD17B10 | |
| SCHEMBL31261706 | 0.80 | SGMS2 (0.84) | SGMS2 | |
| SCHEMBL21056814 | 0.79 | KDM4C (0.50) | KMT2AMEN1HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL15528462 | 0.78 | RXFP1 (1.00) | RXFP1KMT2AMEN1RAB9AMAPK1 | |
| SCHEMBL15528384 | 0.78 | RXFP1 (0.77) | RXFP1KMT2AMEN1SGMS2 | |
| SCHEMBL13322124 | 0.77 | TYK2 (0.67) | KMT2AMEN1RAB9AKCNK3KCNK9 | |
| SCHEMBL15528546 | 0.76 | RXFP1 (0.64) | RXFP1KMT2AMEN1KCNK3KCNK9 | |
| SCHEMBL17551879 | 0.76 | SGMS2 (0.83) | SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | RXFP1 171/4885KMT2A 2272/4885MEN1 3937/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | RXFP1 141/4885KMT2A 1506/4885MEN1 1408/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | RXFP1 141/4885KMT2A 1506/4885MEN1 1408/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | RXFP1 141/4885KMT2A 1506/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.